This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Steinberg, G. K. Articles by Zarnegar, S. R. Search for Related Content PubMed PubMed Citation Articles by Steinberg, G. K. Articles by Zarnegar, S. R. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Hazardous Substances DB (L)-ASPARTIC ACID DEXTROMETHORPHAN LEVORPHANOL Medline Plus Health Information Transient Ischemic Attack

Stroke, Vol 20, 1247-1252, Copyright © 1989 by American Heart Association

ARTICLES

Protective effect of N-methyl-D-aspartate antagonists after focal cerebral ischemia in rabbits

GK Steinberg, J Saleh, D Kunis, R DeLaPaz and SR Zarnegar
Division of Neurosurgery, Stanford University School of Medicine, Stanford, California 94305.

We studied the efficacy of postischemic, systemic treatment with the N- methyl-D-aspartate (NMDA) receptor antagonists dextromethorphan and dextrorphan in a rabbit model of transient focal cerebral ischemia. Twenty-two rabbits underwent 1-hour occlusion of the left internal carotid and anterior cerebral arteries followed by 4.5 hours of reperfusion before sacrifice. One hour after the onset of ischemia, immediately after removing the arterial clips, the rabbits were blindly assigned to treatment with dextromethorphan (20 mg/kg i.v. loading dose followed by 10 mg/kg/hr maintenance infusion, n = 7), dextrorphan (15 mg/kg i.v. loading dose followed by 15 mg/kg/hr maintenance infusion, n = 7), or an equivalent volume of normal saline alone (n = 8). The maintenance infusion of drugs or saline was continued for the duration of the experiment. The formalin-fixed brains were analyzed with magnetic resonance imaging using coronal T2-weighted images, and ischemic neuronal damage was assessed on standard coronal hematoxylin- and- eosin-stained sections. The area of neocortical ischemic neuronal damage was significantly reduced in the groups treated with dextromethorphan (4.2%, p less than 0.01) and dextrorphan (6.1%, p less than 0.01) compared with the controls (36.2%). Magnetic resonance imaging demonstrated significantly smaller areas of cortical edema in the groups treated with dextromethorphan (14.6%, p less than 0.01) and dextrorphan (8.0%, p less than 0.01) compared with the controls (32.9%). These clinically tested antitussives with NMDA-antagonist properties may have therapeutic value in the treatment of human cerebrovascular disease.

This article has been cited by other articles:

				K. Takano, T. Tatlisumak, J. E. Formato, R. A. D. Carano, A. G. Bergmann, L. M. Pullan, T. M. Bare, C. H. Sotak, and M. Fisher Glycine Site Antagonist Attenuates Infarct Size in Experimental Focal Ischemia : Postmortem and Diffusion Mapping Studies Stroke, June 1, 1997; 28(6): 1255 - 1263. [Abstract] [Full Text]

				R. Newcomb, X. Sun, L. Taylor, N. Curthoys, and R. G. Giffard Increased Production of Extracellular Glutamate by the Mitochondrial Glutaminase following Neuronal Death J. Biol. Chem., April 25, 1997; 272(17): 11276 - 11282. [Abstract] [Full Text] [PDF]

				J. C Grotta Prevention and management of stroke Vascular Medicine, March 1, 1991; 2(1): 3 - 17. [PDF]